AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04915092 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoSIE app
Description: The app is a mobile phone application compatible with both iOS and Android operating system. Parents are able to register their children and to keep track of their weight status and activities. The app include five themes: child development, physical activity, healthy food, critical situations, BMI.~Push notification on healthy behaviours, on important event taking place in the province of Reggio Emilia, on food advices based on seasonality and on party tips are constantly delivered by the app.
Study NCT06311903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose of Norepinephrine (NE)
Description: Patients were received resuscitative fluid \[administered at beginning with the arrival of the patient in the emergency department (mean blood pressure >70 mmHg)\] followed by low dose of NE (0.05-0.2 μg/kg/min).
Study NCT06311903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose of Norepinephrine (NE)
Description: Patients were received resuscitative fluid. If there were no response to treatment to resuscitative fluid, they received NE gradually till reach high dose (≥0.3 μg/kg/min).
Study NCT05948423 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tisue Flossing Technique
Description: Experimental Group (Tissue Flossing + conventional therapy) Tissue Flossing involved active and passive movement with elbow wrapped with a floss band made from latex rubber (7m x 2 inch) Floss band was wrapped around the elbow (distal to proximal) using 25% overlapping pattern with an elongation stretch of 25%. During treatment the compression of floss band was measured with modified sphygmomanometer by placing cuff under floss band (which is applied on muscle) and note the pressure on manometer.~Control Group (Conventional Therapy) Conventional therapy was applied for 23 minutes for both groups which include hot pack for 10 minutes, PNF (hold-relax with agonist contraction): It started with a gentle stretch of bicep muscle for 10 seconds followed by isometric contraction for 6 seconds then the patient tried to flex their elbow and the therapist also assisted.
Study NCT05948423 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tisue Flossing Technique
Description: Experimental Group (Tissue Flossing + conventional therapy) Tissue Flossing involved active and passive movement with elbow wrapped with a floss band made from latex rubber (7m x 2 inch) Floss band was wrapped around the elbow (distal to proximal) using 25% overlapping pattern with an elongation stretch of 25%. During treatment the compression of floss band was measured with modified sphygmomanometer by placing cuff under floss band (which is applied on muscle) and note the pressure on manometer.~Control Group (Conventional Therapy) Conventional therapy was applied for 23 minutes for both groups which include hot pack for 10 minutes, PNF (hold-relax with agonist contraction): It started with a gentle stretch of bicep muscle for 10 seconds followed by isometric contraction for 6 seconds then the patient tried to flex their elbow and the therapist also assisted.
Study NCT05233475 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care (EUC)
Description: Enhanced usual care (EUC):~All participants will by a health professional be shortly informed about the typical recovery process, the given reassurance about the prognosis.as well as advice on adaptive illness behaviours post-concussion.
Study NCT05233475 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced usual care (EUC)
Description: Enhanced usual care (EUC):~All participants will by a health professional be shortly informed about the typical recovery process, the given reassurance about the prognosis.as well as advice on adaptive illness behaviours post-concussion.
Study NCT05233475 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Get Going after concussIoN Lite
Description: GAIN Lite:~GAIN Lite in an add-on to EUC, and contains two major components: 1) self-administrated e-learning videos and 2) up to four hours video- or phone sessions with an allocated therapist (either an occupational- or a physiotherapist) during a period of 8 weeks. Health professionals provide feedback and guidance, addressing the specific aims and context of the individual.
Study NCT05017051 — intervention group
Intervention type: BEHAVIORAL
Intervention: Chocolate cake
Description: The participants will have to make a chocolate cake following an imposed recipe at 4 visits (initially (M0), after 12 months (M12), after 24 months (M24) and after 36 months (M36)).
Study NCT05017051 — intervention group
Intervention type: BEHAVIORAL
Intervention: Lego model
Description: The participants will have to build a Lego model at 4 visits (M0, M12, M24 and M36).
Study NCT05017051 — intervention group
Intervention type: DEVICE
Intervention: Measurement of sensorimotor abilities
Description: The measurement of sensorimotor abilities is based on a multi-sensor device called Smart Flat specifically designed for this study at 4 visits (M0, M12, M24 and M36).
Study NCT05017051 — intervention group
Intervention type: OTHER
Intervention: Measurement of facial expression of emotions
Description: Participants will have to evoke an emotionally charged autobiographical story by modulating facial expressions through a mirror at 4 visits (M0, M12, M24 and M36).
Study NCT05627453 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm-in-arm gait training
Description: An older adult walk side-by-side, arm-in-arm with a younger adult while synchronizing steps.
Study NCT05627453 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal gait training
Description: An older adult walk side-by-side, without contact, with a younger adult without step synchronization.
Study NCT05056155 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systane Complete
Description: Propylene glycol 0.6% eye drops for replenishing deficiencies in both the lipid and aqueous layers of the tear film
Study NCT04932135 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Continuous heart rate monitoring
Description: Continuous heart rate monitoring with a wrist worn fitnesstracker
Study NCT05656794 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Standard of care radiotherapy administered as per institutional guidelines.
Study NCT05656794 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Radiotherapy
Description: Standard of care radiotherapy administered as per institutional guidelines.
Study NCT05109000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Chloride 0.9% Inj
Description: 10 mL subcutaneous injection into one randomized anterior thigh of subject
Study NCT05109000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacteriostatic Sodium Chloride 0.9 % INJECTION VIAL (ML)
Description: 10 mL subcutaneous injection into the contralateral anterior thigh of subject
Study NCT05754541 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WeFlow-Tribranch Aortic Arch Stent Graft System
Description: Endovascular treament in patients with aortic arch dissection and aneurysm by WeFlow-Tribranch Aortic Arch Stent Graft System
Study NCT06149104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Description: sacubiril/valsartan
Study NCT06609642 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Art application
Description: First, participants will complete questionnaires that will provide us with their socio-demographic information, their level of knowledge in visual arts and music, as well as their level of eco-anxiety.~Second, participants will use the application on a touchscreen tablet:~1. A member of the research team will give a brief explanation of the application.~2. The participant will use the application on the touchscreen tablet.~3. A member of the research team will be present in the room during the test as an observer.~Third, the participant will answer questions from a member of the research team: impressions of the tool, digital skills and abilities, enablers and barriers to the use of the tool, expectations, needs, and interests in the application.
Study NCT06613256 — intervention group
Intervention type: OTHER
Intervention: Endothelial cell biopsy
Description: Endothelial cell sample collected from the antecubital fossa of patients. A vein in the antecubital fossa is cannulated with a 20 g valveless cannula. A metal guidewire is then passed into the vessel to collect endothelial cells for analysis
Study NCT04777110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: The main anesthesiologist standing on the right side of the patient injects esketamine (0.25 mg/kg) sequentially, and then propofol (1.5 mg/kg) is injected 1 minute later for 30 s;
Study NCT04777110 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: The main anesthesiologist standing on the right side of the patient injects saline (0.05ml/kg) sequentially, and then propofol (1.5 mg/kg) is injected 1 minute later, the injection time is 30 s
Study NCT05262452 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ALPIUS 900, an ultrasound-guided high intensity focused ultrasound system
Description: Device to deliver mechanical stress and force to enhance drug delivery, using focused ultrasound
Study NCT05262452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX regimen
Description: a chemotherapy regimen for treatment of advanced pancreatic cancer~* FOL : folinic acid (leucovorin), a vitamin B derivative that enhances the effects of 5-FU~* F : 5-FU, a pyrimidine analog and antimetabolite which incorporates into the DNA molecule and stops DNA synthesis~* IRIN : irinotecan (eloxatin), a platinum-based antineoplastic agent, which inhibits DNA repair and/or DNA synthesis.~* OX - oxaliplatin (Eloxatin), a platinum-based antineoplastic agent, which inhibits DNA repair and/or DNA synthesis
Study NCT05072210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Intervention
Description: Active mobile data will be used to provide automated, personalized notifications to frontline healthcare workers. Key information on mental health and links to access additional health resources will be available on the mobile platform.
Study NCT06486051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2/day IV for three consecutive days
Study NCT06486051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 500 mg/m\^2/day IV for three consecutive days
Study NCT06486051 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WZTL-002 CAR T-cells
Description: WZTL-002 comprises autologous T-cells transduced to express the third-generation 1928T2z chimeric antigen receptor, which recognises the CD19 antigen present on malignant and normal B-cells. The chimeric antigen receptor (CAR) incorporates an extracellular scFv specific for CD19, the intracellular signalling domains of CD28 and CD3ζ, and an intracellular co-stimulatory domain derived from TLR2 interposed between CD28 and CD3ζ.~On Day 0, the WZTL-002 CAR T-cell product is administered intravenously two days after completing lymphodepleting chemotherapy.
Study NCT04536675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilanterol and Umeclidinium Bromide
Description: Perioperative inhaler therapy with VI/UME (Vilanterol 25mcg/Umeclidinium 62.5mcg) once daily using Ellipta device from at least for 2 weeks preoperatively to at least 16 weeks post operatively.
Study NCT04536675 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Perioperative inhaler therapy with placebo once daily using Ellipta device from at least for 2 weeks preoperatively to at least 16 weeks post operatively.
Study NCT05008445 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LM-102 Injection
Description: LM-102 Injection with dose escalation stage of 3mg/kg up to 40mg/kg, as well as dose expansion stage with recommended dose level from dose escalation stage.
Study NCT05008445 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LM-102 Injection combined with SOC
Description: LM-102 Injection with appropriate dose level(s), combined with SOC.
Study NCT04723589 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thawed plasma
Description: Plasma not labeled convalescent plasma is presumed to be free of COVID antibodies, but is not tested for antibodies. To ensure that we are using antibody-free plasma, we will test each unit of plasma with a quick COVID test before it is utilized in this study.
Study NCT06061237 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Thai dance exercise
Description: Aerobic Thai dance exercise 60 minute per times, 3 times per weeks of 12 weeks. Aerobic exercise of modulate intensity (12-13 Borg's RPE)
Study NCT05656911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zabedosertib (BAY1834845)
Description: Oral administration, two times a day
Study NCT05656911 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to zabedosertib (BAY 1834845)
Description: Oral administration, two times a day
Study NCT05089045 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant new coronavirus vaccine (CHO cell) group
Description: Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
Study NCT06037837 — intervention group
Intervention type: PROCEDURE
Intervention: Robotic Surgery
Description: Surgeons will perform and participants will undergo robotic surgery according to the standard of care. No additional interventions will be performed on participating participants.
Study NCT05988723 — intervention group
Intervention type: OTHER
Intervention: ELISA kits
Description: Making biochemical measurements with the ELISA kit
Study NCT06016218 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Comparing Simvastatin powder with PRF to Bone Powder with PRF on Peri-implant Bone
Study NCT06016218 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simvastatin
Description: Comparing Simvastatin powder with PRF to Bone Powder with PRF on Peri-implant Bone
Study NCT05584358 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dry protein blend ingestion
Description: Ingestion of protein blend powders mixed in water
Study NCT05584358 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Extruded protein blend ingestion
Description: Ingestion of protein blend powders mixed in water
Study NCT04982770 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey
Description: Reading of ethical guidelines.
Study NCT05422053 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: t:slim X2 insulin pump with Control-IQ technology 1.5
Description: t:slim X2 insulin pump with Control-IQ technology 1.5, and wearing the Dexcom G6 CGM.
Study NCT04906681 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: i-ACT
Description: i-ACT is a Microsoft Kinect-based system that provides individualised exercises based on patients own goalsetting.
Study NCT05756296 — intervention group
Intervention type: PROCEDURE
Intervention: Therapeutic hypothermia
Description: whole-body cooling to an esophageal temperature of 33.5°C initiated within the first 6 hours of life, continued for 72 hours, and then they were slowly rewarmed for moderate or severe NE
Study NCT05929989 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA TEST
Description: ELISA TEST for cystatin D and fibrinogen like protein
Study NCT04813107 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: APL-1202 in combination with tislelizumab
Description: For those assigned to this group (1), each patient will receive 3 cycles of treatment prior to RC and each cycle is 3 weeks. On day 1 of each cycle, a single dose of 200 mg tislelizumab will be administered intravenously. APL-1202 will be administered orally TID daily for 3 weeks at the RP2D defined from Phase I.
Study NCT04813107 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tislelizumab alone
Description: For patients assigned to this group (2), each patient will receive 3 cycles of treatments with a single dose of 200 mg tislelizumab administered on day 1 of each cycle, followed by RC.
Study NCT05461352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-142 5 mg
Description: Participants received repeated doses of 5 mg of TS-142 (oral tablet)
Study NCT05461352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-142 10 mg
Description: Participants received repeated doses of 10 mg of TS-142 (oral tablet)
Study NCT05299255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utidelone
Description: Utidelone Versus placebo in Third-line and above treatment of Extensive Small-cell Lung Cancer
Study NCT05299255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: the placebo as control group.
Study NCT05423899 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Grace Robot
Description: The Grace robot was designed by Awakening Health/Hanson Robotics for healthcare settings and to interact with the elderly and those isolated by the COVID-19 pandemic. Grace is a robot with a human-like appearance, which can move, actively listen, engage in conversation and react appropriately to human emotions. Intervention activities will mostly consist of active listening and general discussions about topics of interest (e.g. hobbies, music). The participant will also have the option of other types of interactions with the robot, including robot-led meditation, robot-led light exercise, listening to music and singing. Because loneliness is a subjective experience and does not have a standardized solution, this is a personalized intervention approach. We anticipate that each older adult participant will have different needs and wishes when interacting with the robot, which will allow for a more natural interaction with the robot.
Study NCT05423899 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: The treatment as usual active control group will not receive the robot intervention. The investIgators have deliberately chosen the participating long-term care (LTC) homes due to their high frequency of social interactions for their clients as part of their routine care (e.g. one-on-one and group activities, family interaction, exercise groups) compared to most LTC homes settings, making TAU an active control.
Study NCT06241781 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GT101 injection
Description: GT101 injection to treat cervical cancer
Study NCT06241781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine injection
Description: Gemcitabine injection to treat cervical cancer
Study NCT04238013 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole Body Vibration (WBV)
Description: The WBV session will consist of 8 bouts of 45s vibration (50Hz) with a minute of rest in between each bout.
Study NCT04238013 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electrical Stimulation
Description: The electrical stimulation intervention serves to account for any effects of standing and/or of repeated performance of the sit-to-stand behavior on neurophysiological outcomes. In the electrical stimulation intervention, participants will receive electrical stimulation while standing on the vibration platform for 8 bouts for 45s with a minute of rest in between without vibration.
Study NCT05424146 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Prebiotic Bar +CPT
Description: Participants will be instructed to consume 1 prebiotic bar once daily for 1 week CPT. Starting week 2 they will be asked to consume 1 prebiotic bar twice daily.
Study NCT05424146 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Non-Prebiotic Bar +CPT
Description: Participants will be instructed to consume 1 non-prebiotic bar once daily for 1 week while receiving CPT. Starting week 2 they will be asked to consume 1 non-prebiotic bar twice daily.
Study NCT06236633 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning
Description: Embolization performed via a common right femoral or radial approach, depending on the patient's conformation. Minor complications such as hematoma at the puncture site are rare in less than 1% of cases, and serious complications are exceptional. Proximal occlusion of the inferior mesenteric artery, before its dividing branches, using material adapted to arterial occlusion according to anatomical findings. Proximal occlusion during embolization is evaluated by intravascular injection into the inferior mesenteric artery, and resumption of vascularization of the distal inferior mesenteric artery is controlled by the border arcade injecting into the superior mesenteric artery. In the event of a high-risk anatomical variant, or absence of a border arcade, no embolization will be performed and the patient will be excluded from the study; this will represent no more than 1-2% of patients (surgical series describing 0.83% of ischemia in connection with absence of a border arcade).
Study NCT06236633 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arteriogram
Description: The interventional radiologist performs an arteriogram of the inferior and superior mesenteric arteries (IMA and SMA respectively) to check that the SMA is free of anomalies and that the IMA has a proximal trunk long enough for embolization. The radiologist also checks for the presence of a colonic border arcade. If this is absent, embolization will not be performed: the patient will be excluded from the study.This arteriogram is carried out under local anaesthetic specifically for research purposes, as follows: Common right femoral or radial approach and placement of a small introducer. Selective arteriogram of the inferior and superior mesenteric arteries to check perfusion of the border arcade.Arterial closure system or manual compression. Return to surgery or interventional radiology department. Patient discharged the same day after medical assessment (surgeon or interventional radiologist).Telephone check-up on Day1 (standard management) and Day 7 (added as part of the protocol).